Constrained use of CCR5 on CD4+lymphocytes by R5X4 HIV-1: Efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry

被引:8
作者
Loftin, Lamorris M. [1 ,2 ]
Kienzle, Martha F. [1 ]
Yi, Yanjie [1 ]
Lee, Benhur [3 ]
Lee, Fang-Hua [2 ]
Gray, Lachlan [4 ]
Gorry, Paul R. [4 ]
Collman, Ronald G. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[4] Ctr Virol, Burnet Inst, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
R5X4; HIV-1; CD4+lymphocytes; CCR5; Coreceptor use; Viral entry; tropism; IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCYTE-DERIVED MACROPHAGES; CENTRAL-NERVOUS-SYSTEM; HUMAN LYMPHOID-TISSUE; DUAL-TROPIC HIV-1; CORECEPTOR USAGE; V3; LOOP; BIOLOGICAL PHENOTYPE; IN-VITRO; CCR5-DELTA-32; ALLELE;
D O I
10.1016/j.virol.2010.03.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
R5X4 HIV-1 has impaired utilization of CCR5 on primary CD4+ lymphocytes but the mechanisms responsible are not well defined. Using a panel of diverse R5X4 Envs we identified a spectrum of CCR5 use on CD4+ lymphocytes. Greater lymphocyte CCR5 use correlated with relative resistance to CCR5 mAbs and small molecule antagonists. Increasing CCR5 expression on lymphocytes increased the proportion of entry mediated by CCR5 for all R5X4 isolates except 89.6. In cell lines with regulated CCR5 expression, strains with greater lymphocyte CCR5 use better exploited limiting levels of CCR5. Introduction of an R306S mutation in the 89.6 V3 domain enhanced its utilization of CCR5 at low levels and switched its preference to CCR5 for lymphocyte entry. Thus, the degree to which R5X4 HIV-1 use primary lymphocyte CCR5 is determined by low CCR5 expression coupled with variations in the efficiency of Env-CCR5 interactions, which is in part governed by V3 sequences. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:135 / 148
页数:14
相关论文
共 78 条
[1]  
Bjorndal A, 1997, J VIROL, V71, P7478
[2]   Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies [J].
Blanpain, C ;
Vanderwinden, JM ;
Cihak, J ;
Wittamer, V ;
Le Poul, E ;
Issafras, H ;
Stangassinger, M ;
Vassart, G ;
Marullo, S ;
Schlöndorff, D ;
Parmentier, M ;
Mack, M .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (02) :723-737
[3]   Structural basis for coreceptor selectivity by the HIV type 1 V3 loop [J].
Cardozo, Timothy ;
Kimura, Tetsuya ;
Philpott, Sean ;
Weiser, Barbara ;
Burger, Harold ;
Zolla-Pazner, Susan .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (03) :415-426
[4]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728
[5]   Evolution of CCR5 Use before and during Coreceptor Switching [J].
Coetzer, Mia ;
Nedellec, Rebecca ;
Salkowitz, Janelle ;
McLaughlin, Sherry ;
Liu, Yi ;
Heath, Laura ;
Mullins, James I. ;
Mosier, Donald E. .
JOURNAL OF VIROLOGY, 2008, 82 (23) :11758-11766
[6]   AN INFECTIOUS MOLECULAR CLONE OF AN UNUSUAL MACROPHAGE-TROPIC AND HIGHLY CYTOPATHIC STRAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
COLLMAN, R ;
BALLIET, JW ;
GREGORY, SA ;
FRIEDMAN, H ;
KOLSON, DL ;
NATHANSON, N ;
SRINIVASAN, A .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7517-7521
[7]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[8]   Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120 [J].
Cormier, EG ;
Persuh, M ;
Thompson, DAD ;
Lin, SW ;
Sakmar, TP ;
Olson, WC ;
Dragic, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (11) :5762-5767
[9]   Mapping the determinants of the CCRS amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes [J].
Cormier, EG ;
Tran, DNH ;
Yukhayeva, L ;
Olson, WC ;
Dragic, T .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5541-5549
[10]   SYNCYTIUM-INDUCING (SI) PHENOTYPE SUPPRESSION AT SEROCONVERSION AFTER INTRAMUSCULAR INOCULATION OF A NON-SYNCYTIUM-INDUCING/SI PHENOTYPICALLY MIXED HUMAN-IMMUNODEFICIENCY-VIRUS POPULATION [J].
CORNELISSEN, M ;
MULDERKAMPINGA, G ;
VEENSTRA, J ;
ZORGDRAGER, F ;
KUIKEN, C ;
HARTMAN, S ;
DEKKER, J ;
VANDERHOEK, L ;
SOL, C ;
COUTINHO, R ;
GOUDSMIT, J .
JOURNAL OF VIROLOGY, 1995, 69 (03) :1810-1818